|Ms. Daphne Zohar||Founder, CEO & Executive Director||1.01M||N/A||1971|
|Dr. Bharatt M. Chowrira J.D., Ph.D.||President, Secretary, Chief Business Finance & Operating Officer and Executive Director||800.55k||N/A||1965|
|Dr. Robert S. Langer Jr., Ph.D.||Co-Founder & Non-Executive Director||145k||N/A||1949|
|Dr. David R. Elmaleh Ph.D.||Co-Founder & Senior Advisor||N/A||N/A||1948|
|Ms. Allison Mead Talbot||Head of Communications & Investor Relations||N/A||N/A||N/A|
|Mr. Spencer Ball||Senior Vice President of Human Resources||N/A||N/A||N/A|
|Dr. Eric Elenko Ph.D.||Chief Innovation & Strategy Officer||N/A||N/A||1973|
|Ms. Aleksandra Filipovic M.D., Ph.D.||Head of Oncology||N/A||N/A||N/A|
|Ms. Cheryl Murphy Ph.D.||Head of Grants Management & Strategy||N/A||N/A||N/A|
|Ms. Anita Terpstra J.D., Ph.D.||Senior VP & Head of Intellectual Property||N/A||N/A||N/A|
PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
PureTech Health plc’s ISS Governance QualityScore as of November 1, 2023 is 9. The pillar scores are Audit: 10; Board: 3; Shareholder Rights: 1; Compensation: 10.